A detailed history of Catalys Pacific, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Catalys Pacific, LLC holds 1,122,572 shares of PHAT stock, worth $8.42 Million. This represents 16.19% of its overall portfolio holdings.

Number of Shares
1,122,572
Previous 721,962 55.49%
Holding current value
$8.42 Million
Previous $7.44 Billion 172.94%
% of portfolio
16.19%
Previous 5.61%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.25 - $19.5 $4.11 Million - $7.81 Million
400,610 Added 55.49%
1,122,572 $20.3 Billion
Q4 2023

Feb 14, 2024

BUY
$6.99 - $10.71 $5.05 Million - $7.73 Million
721,962 New
721,962 $6.59 Billion

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $294M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Catalys Pacific, LLC Portfolio

Follow Catalys Pacific, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalys Pacific, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Catalys Pacific, LLC with notifications on news.